Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 136

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 136
---
-offs of option assets.

Table of Contents

                                                                           For the Year Ended March 31, 2023                                                                                                                                                                                 
                                                                           Reported                                            Amortization of intangible assets      Impairment of intangible assets      Other operating income/expenses (2)      Others (3)      Core Financial Measures  
                                                                           (IFRS)                                                                                                                                                                                   (non-IFRS)               
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
                                                                           (billions of yen)                                                                                                                                                                                                 
  Revenue                                                                  ¥                                      4,027.5      ¥                                      ¥                                    ¥                                        ¥               ¥                        
  Cost of sales                                                            (1,244.1)                                           —                                      —                                    —                                        35.7            (1,208.4)                
  Selling, general and administrative expenses                             (997.3)                                             —                                      —                                    —                                        (0.0)           (997.3)                  
  Research and development expenses                                        (633.3)                                             —                                      —                                    —                                        (0.0)           (633.4)                  
  Amortization of intangible assets associated with products               (485.1)                                             485.1                                  —                                    —                                        —               —                        
  Impairment losses on intangible assets associated with products (1)      (57.3)                                              —                                      57.3                                 —                                        —               —                        
  Other operating income (expenses)                                        (119.8)                                             —                                      —                                    119.8                                    —               —                        
  Operating profit                                                         ¥                                        490.5      ¥                                      ¥                                    ¥                                        ¥               ¥                        

___________

Notes:

(1) Intangible assets associated with products include in-process R& D (IPR& D).

(2) Other operating income/expenses include changes in fair value of financial assets and liabilities associated with contingent consideration arrangements, gains/losses on sales of property, plant and equipment and investment property, change in estimate of liabilities related to SHP647, donations and contributions, rental income and lease expense for sublease, restructuring expenses, valuation reserves for pre-launch inventories, impairment of assets held for sale, legal provisions and write-offs of option assets.

(3) Others: cost of sales includes expenses related to the COVID-19 pandemic and the unwinding of acquisition accounting adjustments (i. e., step up) in value of inventory and PP& E